Intravenous Immunoglobulin Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major intravenous immunoglobulin markets reached a value of US$ 12.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 23.5 Billion by 2034, exhibiting a growth rate (CAGR) of 5.76% during 2024-2034.
The intravenous immunoglobulin market has been comprehensively analyzed in IMARC's new report titled "Intravenous Immunoglobulin Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Intravenous immunoglobulin (IVIG) refers to a pooled antibody and biological agent derived from human blood plasma. It is used to treat a wide range of medical conditions that affect the immune system and cause a deficiency of antibodies. The composition of IVIG products is similar to that of immunoglobulins found in normal human plasma, including IgG, IgA, traces of other Igs, soluble receptors, cytokines, etc. Based on the formulation, it is generally administered by injecting into a muscle, vein, or under the skin. IVIG can be utilized in various treatment protocols, including replacement therapy for patients with primary and secondary immunodeficiencies. It may also be used to aid in the prevention of infections in individuals who have undergone an organ or stem cell transplant. This therapy offers numerous advantages, such as low toxicity, targeted delivery, long-term effectiveness, quicker onset of action, etc. The dosage and frequency of IVIG treatment depend on the specific condition being treated and the patient's individual needs.
The rising incidence of immunodeficiency disorders, such as acquired immunodeficiency syndrome (AIDS) and primary immunodeficiency diseases (PIDs), is primarily driving the intravenous immunoglobulin market. In addition to this, the expanding geriatric population, who are more susceptible to infections and other immune-related ailments, is further creating a positive outlook for the market. Moreover, the emerging popularity of subcutaneous administration of IVIG on account of its several benefits over intravenous administration, such as a lower risk of infection, reduced incidence of infusion-related reactions, convenience, etc., is acting as another significant growth-inducing factor. Besides this, the escalating utilization of off-label IVIG for numerous indications, including inflammatory bowel disease, dermatological conditions, neurological disorders, etc., since it modulates the immune system and provides the body with antibodies, is also bolstering the market growth. Furthermore, the ongoing advancements in formulation and stabilization techniques that have increased the efficiency and scale of production, thereby lowering the cost of the therapy, are expected to drive the intravenous immunoglobulin market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the intravenous immunoglobulin market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for intravenous immunoglobulin and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the intravenous immunoglobulin market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the intravenous immunoglobulin market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the intravenous immunoglobulin market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current intravenous immunoglobulin marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the intravenous immunoglobulin market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the intravenous immunoglobulin market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the intravenous immunoglobulin market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of intravenous immunoglobulin across the seven major markets?
What is the number of prevalent cases (2018-2034) of intravenous immunoglobulin by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of intravenous immunoglobulin by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with intravenous immunoglobulin across the seven major markets?
What is the size of the intravenous immunoglobulin patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of intravenous immunoglobulin?
What will be the growth rate of patients across the seven major markets?
Intravenous Immunoglobulin: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for intravenous immunoglobulin drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the intravenous immunoglobulin market?
What are the key regulatory events related to the intravenous immunoglobulin market?
What is the structure of clinical trial landscape by status related to the intravenous immunoglobulin market?
What is the structure of clinical trial landscape by phase related to the intravenous immunoglobulin market?
What is the structure of clinical trial landscape by route of administration related to the intravenous immunoglobulin market?
The intravenous immunoglobulin market has been comprehensively analyzed in IMARC's new report titled "Intravenous Immunoglobulin Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Intravenous immunoglobulin (IVIG) refers to a pooled antibody and biological agent derived from human blood plasma. It is used to treat a wide range of medical conditions that affect the immune system and cause a deficiency of antibodies. The composition of IVIG products is similar to that of immunoglobulins found in normal human plasma, including IgG, IgA, traces of other Igs, soluble receptors, cytokines, etc. Based on the formulation, it is generally administered by injecting into a muscle, vein, or under the skin. IVIG can be utilized in various treatment protocols, including replacement therapy for patients with primary and secondary immunodeficiencies. It may also be used to aid in the prevention of infections in individuals who have undergone an organ or stem cell transplant. This therapy offers numerous advantages, such as low toxicity, targeted delivery, long-term effectiveness, quicker onset of action, etc. The dosage and frequency of IVIG treatment depend on the specific condition being treated and the patient's individual needs.
The rising incidence of immunodeficiency disorders, such as acquired immunodeficiency syndrome (AIDS) and primary immunodeficiency diseases (PIDs), is primarily driving the intravenous immunoglobulin market. In addition to this, the expanding geriatric population, who are more susceptible to infections and other immune-related ailments, is further creating a positive outlook for the market. Moreover, the emerging popularity of subcutaneous administration of IVIG on account of its several benefits over intravenous administration, such as a lower risk of infection, reduced incidence of infusion-related reactions, convenience, etc., is acting as another significant growth-inducing factor. Besides this, the escalating utilization of off-label IVIG for numerous indications, including inflammatory bowel disease, dermatological conditions, neurological disorders, etc., since it modulates the immune system and provides the body with antibodies, is also bolstering the market growth. Furthermore, the ongoing advancements in formulation and stabilization techniques that have increased the efficiency and scale of production, thereby lowering the cost of the therapy, are expected to drive the intravenous immunoglobulin market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the intravenous immunoglobulin market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for intravenous immunoglobulin and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the intravenous immunoglobulin market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the intravenous immunoglobulin market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the intravenous immunoglobulin market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current intravenous immunoglobulin marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the intravenous immunoglobulin market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the intravenous immunoglobulin market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the intravenous immunoglobulin market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of intravenous immunoglobulin across the seven major markets?
What is the number of prevalent cases (2018-2034) of intravenous immunoglobulin by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of intravenous immunoglobulin by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with intravenous immunoglobulin across the seven major markets?
What is the size of the intravenous immunoglobulin patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of intravenous immunoglobulin?
What will be the growth rate of patients across the seven major markets?
Intravenous Immunoglobulin: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for intravenous immunoglobulin drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the intravenous immunoglobulin market?
What are the key regulatory events related to the intravenous immunoglobulin market?
What is the structure of clinical trial landscape by status related to the intravenous immunoglobulin market?
What is the structure of clinical trial landscape by phase related to the intravenous immunoglobulin market?
What is the structure of clinical trial landscape by route of administration related to the intravenous immunoglobulin market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRAVENOUS IMMUNOGLOBULIN - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 INTRAVENOUS IMMUNOGLOBULIN - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 INTRAVENOUS IMMUNOGLOBULIN - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 INTRAVENOUS IMMUNOGLOBULIN - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 INTRAVENOUS IMMUNOGLOBULIN - UNMET NEEDS
10 INTRAVENOUS IMMUNOGLOBULIN - KEY ENDPOINTS OF TREATMENT
11 INTRAVENOUS IMMUNOGLOBULIN - MARKETED PRODUCTS
11.1 List of Intravenous Immunoglobulin Marketed Drugs Across the Top 7 Markets
11.1.1 Asceniv (Immune globulin) - ADMA Biologics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Bivigam (Immunoglobulin G) - ADMA Biologics
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Flebogamma (Immune globulin) - Grifols
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Gammagard Liquid (Immune globulin) - Takeda Pharmaceutical
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Panzyga (Immune globulin 10%) - Octapharma
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 INTRAVENOUS IMMUNOGLOBULIN - PIPELINE DRUGS
12.1 List of Intravenous Immunoglobulin Pipeline Drugs Across the Top 7 Markets
12.1.1 GC 5107 - GC Biopharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 NPB-01 - Nihon Pharmaceutical
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 GB 0998 - Mitsubishi Tanabe Pharma
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 BT 595 - Biotest
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. INTRAVENOUS IMMUNOGLOBULIN - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. INTRAVENOUS IMMUNOGLOBULIN – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 INTRAVENOUS IMMUNOGLOBULIN - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Intravenous Immunoglobulin - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Intravenous Immunoglobulin - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Intravenous Immunoglobulin - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Intravenous Immunoglobulin - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Intravenous Immunoglobulin - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Intravenous Immunoglobulin - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Intravenous Immunoglobulin - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Intravenous Immunoglobulin - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Intravenous Immunoglobulin - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Intravenous Immunoglobulin - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Intravenous Immunoglobulin - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Intravenous Immunoglobulin - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Intravenous Immunoglobulin - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Intravenous Immunoglobulin - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Intravenous Immunoglobulin - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Intravenous Immunoglobulin - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Intravenous Immunoglobulin - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Intravenous Immunoglobulin - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Intravenous Immunoglobulin - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Intravenous Immunoglobulin - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Intravenous Immunoglobulin - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Intravenous Immunoglobulin - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Intravenous Immunoglobulin - Access and Reimbursement Overview
16 INTRAVENOUS IMMUNOGLOBULIN - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 INTRAVENOUS IMMUNOGLOBULIN MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 INTRAVENOUS IMMUNOGLOBULIN MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRAVENOUS IMMUNOGLOBULIN - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 INTRAVENOUS IMMUNOGLOBULIN - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 INTRAVENOUS IMMUNOGLOBULIN - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 INTRAVENOUS IMMUNOGLOBULIN - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 INTRAVENOUS IMMUNOGLOBULIN - UNMET NEEDS
10 INTRAVENOUS IMMUNOGLOBULIN - KEY ENDPOINTS OF TREATMENT
11 INTRAVENOUS IMMUNOGLOBULIN - MARKETED PRODUCTS
11.1 List of Intravenous Immunoglobulin Marketed Drugs Across the Top 7 Markets
11.1.1 Asceniv (Immune globulin) - ADMA Biologics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Bivigam (Immunoglobulin G) - ADMA Biologics
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Flebogamma (Immune globulin) - Grifols
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Gammagard Liquid (Immune globulin) - Takeda Pharmaceutical
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Panzyga (Immune globulin 10%) - Octapharma
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 INTRAVENOUS IMMUNOGLOBULIN - PIPELINE DRUGS
12.1 List of Intravenous Immunoglobulin Pipeline Drugs Across the Top 7 Markets
12.1.1 GC 5107 - GC Biopharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 NPB-01 - Nihon Pharmaceutical
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 GB 0998 - Mitsubishi Tanabe Pharma
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 BT 595 - Biotest
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. INTRAVENOUS IMMUNOGLOBULIN - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. INTRAVENOUS IMMUNOGLOBULIN – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 INTRAVENOUS IMMUNOGLOBULIN - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Intravenous Immunoglobulin - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Intravenous Immunoglobulin - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Intravenous Immunoglobulin - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Intravenous Immunoglobulin - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Intravenous Immunoglobulin - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Intravenous Immunoglobulin - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Intravenous Immunoglobulin - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Intravenous Immunoglobulin - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Intravenous Immunoglobulin - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Intravenous Immunoglobulin - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Intravenous Immunoglobulin - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Intravenous Immunoglobulin - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Intravenous Immunoglobulin - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Intravenous Immunoglobulin - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Intravenous Immunoglobulin - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Intravenous Immunoglobulin - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Intravenous Immunoglobulin - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Intravenous Immunoglobulin - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Intravenous Immunoglobulin - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Intravenous Immunoglobulin - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Intravenous Immunoglobulin - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Intravenous Immunoglobulin - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Intravenous Immunoglobulin - Access and Reimbursement Overview
16 INTRAVENOUS IMMUNOGLOBULIN - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 INTRAVENOUS IMMUNOGLOBULIN MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 INTRAVENOUS IMMUNOGLOBULIN MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
